keyword
MENU ▼
Read by QxMD icon Read
search

nrti

keyword
https://www.readbyqxmd.com/read/28495562/nucleoside-reverse-transcriptase-inhibitor-cross-resistance-and-outcomes-from-second-line-antiretroviral-therapy-in-the-public-health-approach-an-observational-analysis-within-the-randomised-open-label-earnest-trial
#1
Nicholas I Paton, Cissy Kityo, Jennifer Thompson, Immaculate Nankya, Leonard Bagenda, Anne Hoppe, James Hakim, Andrew Kambugu, Joep J van Oosterhout, Mary Kiconco, Silvia Bertagnolio, Philippa J Easterbrook, Peter Mugyenyi, A Sarah Walker
BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the association between the activity, predicted by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients infected with HIV. METHODS: We did an observational analysis of additional data from a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa...
May 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28477212/efficacy-and-tolerability-of-switching-to-a-dual-therapy-with-darunavir-ritonavir-plus-raltegravir-in-hiv-infected-patients-with-hiv-1-rna-%C3%A2-50%C3%A2-cp-ml
#2
Giordano Madeddu, Stefano Rusconi, Alessandro Cozzi-Lepri, Simona Di Giambenedetto, Stefano Bonora, Alessia Carbone, Andrea De Luca, Nicola Gianotti, Antonio Di Biagio, Andrea Antinori
BACKGROUND: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. OBJECTIVES: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting...
May 5, 2017: Infection
https://www.readbyqxmd.com/read/28474534/evolution-of-hiv-1-surveillance-drug-resistance-mutations-over-ten-years-in-new-south-wales-australia
#3
Angie Pinto, Alex Carrera, Hanan Salem, Kiran Thapa, Ansari Shaik, Kathy Petoumenos, Philip Cunningham, Roger Garsia, Dominic Dwyer, David A Cooper, Anthony D Kelleher
New South Wales (NSW) has the greatest burden of HIV in Australia, with 2012 and 2013 recording the highest rates of new diagnoses in twenty years. Concurrently, there has been significant changes in antiretorviral treatments and testing paradigms. We compiled a statewide resistance database to characterize changes in HIV-1 resistance mutations over time. Genotypic antiretroviral resistance testing (GART) was performed on request at three reference laboratories using commercial and in house methods. 7629 HIV-1 polymerase sequences obtained from GART from 2004-2013 were retrospectively collated, reformatted, de-identified and analysed using Stanford HIVdb program 7...
May 5, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28447585/metabolic-profiles-of-individuals-switched-to-second-line-antiretroviral-therapy-after-failing-standard-first-line-therapy-for-treatment-of-hiv-1-infection-in-a-randomized-controlled-trial
#4
Amanda H Yao, Cecilia L Moore, Poh Lian Lim, Jean-Michel Molina, Juan Sierra Madero, Stephen Kerr, Paddy Wg Mallon, Sean Emery, David A Cooper, Mark A Boyd
BACKGROUND: To investigate metabolic changes associated with second-line antiretroviral therapy (ART) following virological failure of first-line ART. METHODS: SECOND-LINE was an open-label randomized controlled trial. Participants were randomized 1:1 to receive ritonavir-boosted lopinavir (LPV/r) with 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI-group) or raltegravir (RAL-group) Two hundred and ten participants had a dual energy X-ray absorptiometry (DXA)-scan at baseline, week 48 and 96...
April 27, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28390117/different-cell-cycle-modulation-in-skov-3-ovarian-cancer-cell-line-by-anti-hiv-drugs
#5
Angelica Perna, Angela Lucariello, Carmine Sellitto, Iolanda Agliata, Maria Carleo, Vincenzo Sangiovanni, Vincenzo Esposito, Germano Guerra, Luigi Cobellis, Antonio De Luca
Anti-retroviral drugs used for the treatment of Human Immunodeficiency Virus (HIV) have proven to be effective even against cancer. Drawing from this background the aim of our research project was to evaluate the effects of anti-HIV drugs that belong to the Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI, abacavir and tenofovir), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI, efavirenz and etravirine) and Protease Inhibitors (PI, darunavir) on ovarian adenocarcinoma cell line (Skov-3)...
March 26, 2017: Oncology Research
https://www.readbyqxmd.com/read/28379449/an-association-between-k65r-and-hiv-1-subtype-c-viruses-in-patients-treated-with-multiple-nrtis
#6
Erasmus Smit, Ellen White, Duncan Clark, Duncan Churchill, Hongyi Zhang, Simon Collins, Deenan Pillay, Caroline Sabin, Mark Nelson, Alan Winston, Sophie Jose, Anna Tostevin, David T Dunn
Objectives: HIV-1 subtype C might have a greater propensity to develop K65R mutations in patients with virological failure compared with other subtypes. However, the strong association between viral subtype and confounding factors such as exposure groups and ethnicity affects the calculation of this propensity. We exploited the diversity of viral subtypes within the UK to undertake a direct comparative analysis. Patients and methods: We analysed only sequences with major IAS-defined mutations from patients with virological failure...
April 3, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28375875/emergent-drug-resistance-with-integrase-strand-transfer-inhibitor-based-regimens-incidence-and-risk-factors
#7
Katherine J Lepik, P Richard Harrigan, Benita Yip, Lu Wang, Marjorie A Robbins, Wendy W Zhang, Junine Toy, Linda Akagi, Viviane Dias Lima, Silvia Guillemi, Julio S G Montaner, Rolando Barrios
OBJECTIVES: To estimate the incidence of and risk factors for emergent resistance to integrase inhibitors (INSTI) and nucleoside(-tide) reverse transcriptase inhibitors (NRTI) in HIV-1-infected adults receiving an INSTI plus two NRTIs. DESIGN: Retrospective cohort study. METHODS: Persons ≥19 years were included if they received their first prescription for raltegravir, elvitegravir or dolutegravir in British Columbia, Canada in 2012-2014, and were followed to 31-Dec-2015...
April 3, 2017: AIDS
https://www.readbyqxmd.com/read/28373843/antihyperalgesic-activities-of-endocannabinoids-in-a-mouse-model-of-antiretroviral-induced-neuropathic-pain
#8
Neha Munawar, Mabayoje A Oriowo, Willias Masocha
Background: Nucleoside reverse transcriptase inhibitors (NRTIs) are the cornerstone of the antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). However, their use is sometimes limited by the development of a painful sensory neuropathy, which does not respond well to drugs. Smoked cannabis has been reported in clinical trials to have efficacy in relieving painful HIV-associated sensory neuropathy. Objectives: The aim of this study was to evaluate whether the expression of endocannabinoid system molecules is altered during NRTI-induced painful neuropathy, and also whether endocannabinoids can attenuate NRTI-induced painful neuropathy...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28365230/mutational-correlates-of-virological-failure-in-individuals-receiving-a-who-recommended-tenofovir-containing-first-line-regimen-an-international-collaboration
#9
Soo-Yon Rhee, Vici Varghese, Susan P Holmes, Gert U Van Zyl, Kim Steegen, Mark A Boyd, David A Cooper, Sabin Nsanzimana, Shanmugam Saravanan, Charlotte Charpentier, Tulio de Oliveira, Mary-Ann A Etiebet, Federico Garcia, Dominique Goedhals, Perpetua Gomes, Huldrych F Günthard, Raph L Hamers, Christopher J Hoffmann, Gillian Hunt, Awachana Jiamsakul, Pontiano Kaleebu, Phyllis Kanki, Rami Kantor, Bernhard Kerschberger, Vincent C Marconi, Jean D'amour Ndahimana, Nicaise Ndembi, Nicole Ngo-Giang-Huong, Casper Rokx, Maria M Santoro, Jonathan M Schapiro, Daniel Schmidt, Lillian Seu, Kim C E Sigaloff, Sunee Sirivichayakul, Lindiwe Skhosana, Henry Sunpath, Michele Tang, Chunfu Yang, Sergio Carmona, Ravindra K Gupta, Robert W Shafer
Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on a WHO-recommended TDF-containing first-line regimen. However, the full spectrum of reverse transcriptase (RT) mutations selected in individuals with VF on such a regimen is not known. To identify TDF regimen-associated mutations (TRAMs), we compared the proportion of each RT mutation in 2873 individuals with VF on a WHO-recommended first-line TDF-containing regimen to its proportion in a cohort of 50,803 antiretroviral-naïve individuals...
April 2017: EBioMedicine
https://www.readbyqxmd.com/read/28342180/metabolic-syndrome-in-patients-on-first-line-antiretroviral-therapy-containing-zidovudine-or-tenofovir-in-rural-lesotho-southern-africa
#10
Niklaus Daniel Labhardt, Urs Franz Müller, Isaac Ringera, Jochen Ehmer, Mokete M Motlatsi, Karolin Pfeiffer, Michael A Hobbins, Josephine A Muhairwe, Juergen Muser, Christoph Hatz
OBJECTIVE: To assess the prevalence of metabolic syndrome (MetS) among patients in rural Lesotho who are taking first-line antiretroviral therapy (ART) containing either zidovudine or tenofovir disoproxil. METHODS: Cross-sectional survey in 10 facilities in Lesotho among adult (≥16 years) patients on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART for ≥6 months. MetS was defined according to the International Diabetes Federation criteria...
March 25, 2017: Tropical Medicine & International Health: TM & IH
https://www.readbyqxmd.com/read/28333295/drug-resistance-in-antiretroviral-naive-children-newly-diagnosed-with-hiv-1-in-manaus-amazonas
#11
Solange Dourado de Andrade, Meritxell Sabidó, Wuelton Marcelo Monteiro, Adele Schwartz Benzaken, Amilcar Tanuri
Objectives: To determine the prevalence of drug resistance mutations (DRM), the prevalence of drug susceptibility [transmitted drug resistance (TDR)] and the prevalence of HIV-1 variants among treatment-naive HIV-infected children in Manaus, Amazonas state, Brazil. Methods: Children born to HIV-infected mothers and diagnosed with HIV in an HIV reference service centre and with available pol sequence between 2010 and 2015 prior to antiretroviral initiation were included...
June 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28333232/prevalence-of-hiv-1-drug-resistance-in-treated-patients-with-viral-load-50%C3%A2-copies-ml-a-2014-french-nationwide-study
#12
L Assoumou, C Charpentier, P Recordon-Pinson, M Grudé, C Pallier, L Morand-Joubert, S Fafi-Kremer, A Krivine, B Montes, V Ferré, M Bouvier-Alias, J-C Plantier, J Izopet, M-A Trabaud, S Yerly, J Dufayard, C Alloui, L Courdavault, H Le Guillou-Guillemette, A Maillard, C Amiel, A Vabret, C Roussel, S Vallet, J Guinard, A Mirand, A Beby-Defaux, F Barin, A Allardet-Servent, R Ait-Namane, M Wirden, C Delaugerre, V Calvez, M-L Chaix, D Descamps, S Reigadas
Background: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance. Methods: The HIV-1 protease and reverse transcriptase (RT) and integrase genes were sequenced in plasma samples from 782 consecutive patients on failing antiretroviral regimens, seen in 37 specialized centres in 2014...
June 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28329343/commonly-transmitted-hiv-1-drug-resistance-mutations-in-reverse-transcriptase-and-protease-in-antiretroviral-treatment-na%C3%A3-ve-patients-do-not-affect-response-to-tenofovir-disoproxil-fumarate-or-tenofovir-alafenamide-containing-regimens
#13
Nicolas A Margot, Pamela Wong, Rima Kulkarni, Kirsten White, Danielle Porter, Michael E Abram, Christian Callebaut, Michael D Miller
Background.: The presence of transmitted drug-resistance mutations (TDRM) in antiretroviral (ARV) treatment-naïve patients can adversely affect the outcome of ARV therapy. Methods.: Resistance testing was conducted in 6704 ARV-naïve subjects predominantly from the U.S. and Europe in 9 Gilead clinical studies from 2000 to 2013. Results.: The presence of TDRM increased during this period (5.2% to 11.4%), primarily driven by non-nucleoside RT inhibitor resistance mutations (NNRTI; 0...
January 30, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28322067/the-future-of-pre-exposure-prophylaxis-prep-for-human-immunodeficiency-virus-hiv-infection
#14
Ayşe Elif Özdener, Tae Eun Park, Julie Kalabalik, Rachna Gupta
People at high risk for HIV acquisition should be offered pre-exposure prophylaxis (PrEP). Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is currently the only medication recommended for pre-exposure prophylaxis (PrEP) by the Centers for Disease Control and Prevention (CDC) in people at high risk for HIV acquisition. This article will review medications currently under investigation and the future landscape of PrEP therapy. Areas covered: This article will review clinical trials that have investigated nontraditional regimens of TDF/FTC, antiretroviral agents from different drug classes such as integrase strand transfer inhibitors (INSTI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) as potential PrEP therapies...
May 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28303753/efficacy-and-safety-of-emtricitabine-tenofovir-alafenamide-ftc-taf-vs-emtricitabine-tenofovir-disoproxil-fumarate-ftc-tdf-as-a-backbone-for-treatment-of-hiv-1-infection-in-virologically-suppressed-adults-subgroup-analysis-by-third-agent-of-a-randomized-double
#15
Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, Adriano Lazzarin, Jacques Reynes, Franco Maggiolo, Mingjin Yan, Michael E Abram, Cecilia Tran-Muchowski, Andrew Cheng, Martin S Rhee
BACKGROUND: FTC/TAF was shown to be noninferior to FTC/TDF with advantages in markers of renal and bone safety. OBJECTIVE: To evaluate the efficacy and safety of switching to FTC/TAF from FTC/TDF by third agent (boosted protease inhibitor [PI] vs. unboosted third agent). METHODS: We conducted a 48-week subgroup analysis based on third agent from a randomized, double blind study in virologically suppressed adults on a FTC/TDF-containing regimen who switched to FTC/TAF vs...
March 17, 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28303602/agreement-between-an-in-house-replication-competent-and-a-reference-replication-defective-recombinant-virus-assay-for-measuring-phenotypic-resistance-to-hiv-1-protease-reverse-transcriptase-and-integrase-inhibitors
#16
Francesco Saladini, Alessia Giannini, Adele Boccuto, Ilaria Vicenti, Maurizio Zazzi
BACKGROUND: Although clinical management of drug resistance is routinely based on genotypic methods, phenotypic assays remain necessary for the characterization of novel HIV-1 inhibitors, particularly against common drug-resistant variants. We describe the development and assessment of the performance of a recombinant virus assay for measuring HIV-1 susceptibility to protease (PR), reverse transcriptase (RT), and integrase (IN) inhibitors. METHODS: The system is based on the creation of replication-competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions has been deleted through inverse PCR...
March 17, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/28301548/hiv-1-genetic-diversity-and-antiretroviral-drug-resistance-among-individuals-from-roraima-state-northern-brazil
#17
André de Lima Guerra Corado, Gonzalo Bello, Renato Augusto Carvalho Leão, Fabiana Granja, Felipe Gomes Naveca
The HIV-1 epidemic in Brazil has spread towards the Northern country region, but little is known about HIV-1 subtypes and prevalence of HIV strains with resistance mutations to antiretrovirals in some of the Northern states. HIV-1 protease (PR) and reverse transcriptase (RT) sequences were obtained from 73 treatment-naive and -experienced subjects followed between 2013 and 2014 at a public health reference unit from Roraima, the northernmost Brazilian state. The most prevalent HIV-1 clade observed in the study population was the subtype B (91%), followed by subtype C (9%)...
2017: PloS One
https://www.readbyqxmd.com/read/28298195/role-of-systemic-inflammation-scores-for-prediction-of-clinical-outcomes-in-patients-treated-with-atazanavir-not-boosted-by-ritonavir-in-the-italian-master-cohort
#18
Maria Concetta Postorino, Mattia Prosperi, Emanuele Focà, Eugenia Quiros-Roldan, Elisa Di Filippo, Franco Maggiolo, Alberto Borghetti, Nicoletta Ladisa, Massimo Di Pietro, Andrea Gori, Laura Sighinolfi, Angelo Pan, Nicola Mazzini, Carlo Torti
BACKGROUND: Atazanavir (ATV) not boosted by ritonavir (uATV) has been frequently used in the past for switching combination antiretroviral therapy (cART). However, the clinical outcomes and predictors of such strategy are unknown. METHODS: An observational study was carried out on the Italian MASTER, selecting HIV infected patients on cART switching to an uATV-containing regimen. Baseline was set as the last visit before uATV initiation. In the primary analysis, a composite clinical end-point was defined as the first occurring of any condition among: liver, cardiovascular, kidney, diabetes, non AIDS related cancer or death events...
March 15, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28272247/high-levels-of-virological-failure-with-major-genotypic-resistance-mutations-in-hiv-1-infected-children-after-5-years-of-care-according-to-who-recommended-1st-line-and-2nd-line-antiretroviral-regimens-in-the-central-african-republic-a-cross-sectional-study
#19
Christian Diamant Mossoro-Kpinde, Jean-Chrysostome Gody, Ralph-Sydney Mboumba Bouassa, Olivia Mbitikon, Mohammad-Ali Jenabian, Leman Robin, Mathieu Matta, Kamal Zeitouni, Jean De Dieu Longo, Cecilia Costiniuk, Gérard Grésenguet, Ndèye Coumba Touré Kane, Laurent Bélec
A large cohort of 220 HIV-1-infected children (median [range] age: 12 [4-17] years) was cared and followed up in the Central African Republic, including 198 in 1st-line and 22 in 2nd-line antiretroviral regimens. Patients were monitored clinically and biologically for HIV-1 RNA load and drug resistance mutations (DRMs) genotyping. A total of 87 (40%) study children were virological responders and 133 (60%) nonresponders. In children with detectable viral load, the majority (129; 97%) represented a virological failure...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28253476/virological-suppression-in-children-and-adolescents-is-not-influenced-by-genotyping-but-depends-on-optimal-adherence-to-antiretroviral-therapy
#20
Juliana Costa de Abreu, Sara Nunes Vaz, Eduardo Martins Netto, Carlos Brites
OBJECTIVE: To evaluate the virological outcomes in children and adolescents infected with HIV-1 in Salvador, Bahia according to genotyping results. METHODS: We retrospectively evaluated the rates of virological suppression of children and adolescents submitted to HIV-1 genotyping test from January/2008 to December/2012. The participants were followed in the two referral centers for pediatric AIDS care, in Salvador, Brazil. Resistance mutations, drug sensitivity profiles, and viral subtypes were analyzed using the Stanford HIV-1 Drug Resistance Database...
February 27, 2017: Brazilian Journal of Infectious Diseases
keyword
keyword
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"